Status | Study |
ACTIVE_NOT_RECRUITING |
Study Name: A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2023-07-21 Interventions: As provided in real-world setting |
RECRUITING |
Study Name: Actium-225-Prostate Specific Membrane Antigen Imaging & Therapy Condition: Date: 2023-05-24 Interventions: To evaluate the tolerability and safety of 225Ac-PSMA I&T in patients with metastatic prostate cancer |
NOT_YET_RECRUITING |
Study Name: Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2023-01-30 Interventions: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol |
Recruiting |
Study Name: IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen Condition: Prostatic Neoplasms, Castration-Resistant Date: 2017-01-09 Interventions: Drug: Atezolizumab Atezolizuma |
Not yet recruiting |
Study Name: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Condition: Castration-Resistant Prostatic Cancer Metastatic Prostate Carcinoma Date: 2016-12-01 Interventions: Biological: GnRH agonist/antagonist |
Not yet recruiting |
Study Name: A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Prostate Cancer Date: 2016-11-14 Interventions: Other: Exercise Intervention V |
Not yet recruiting |
Study Name: Combination Study of Guadecitabine and Pembrolizumab. Condition: Castration-Resistant Prostatic Cancer Non Small Cell Lung Cancer Date: 2016-11-02 Interventions: Drug: Guadecitabine In arm 1 ( |
Withdrawn |
Study Name: A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-09-15 Interventions: Drug: JNJ-809 JNJ-809 (1*10^9) |
Not yet recruiting |
Study Name: Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) Condition: Prostatic Cancer, Castration-Resistant Date: 2016-08-08 Interventions: Drug: SXL01 |
Not yet recruiting |
Study Name: Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) Condition: Prostatic Neoplasms, Castration-Resistant Date: 2016-07-19 Interventions: Drug: Xofigo (Radium-223 dichloride, BAY88-8223 Xofigo is indicated for the treatment of patients with c |